Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

Ambys Launches with $140M Plus Takeda Partnership, OncoSec Enters Research Collaboration Agreement with UCLA, Harpoon Therapeutics Treats First Prostate Cancer Patient with HPN424

  • 2018-08-10T22:26:00.000+0000
  • California
  • Author: Lauren Panetta

8/8/18 – Endpoints News
Third Rock’s Ambys hauls $140M for liver disease, inking Takeda deal ahead of launch

8/8/18 – Cellular Biomedicine Group
Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights

8/8/18 – Alector
Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia

8/8/18 – Heron Therapeutics
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress

8/7/18 – Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights

8/7/18 – NovaBay Pharma
NovaBay Pharma Reports Second Quarter 2018 Financial Results

8/7/18 – FibroGen
FibroGen Reports Second Quarter 2018 Financial Results

8/7/18 – Scripps Research
Researchers look to worms for a new model of a peripheral nervous system disease

8/7/18 – Halozyme
Halozyme Reports Second Quarter 2018 Results

8/6/18 – Biocept
Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs

8/6/18 – OncoSec
OncoSec Enters Research Collaboration Agreement with UCLA and Roger S. Lo, M.D., Ph.D.

8/6/18 – Otonomy
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication

8/6/18 – Harpoon Therapeutics
Harpoon Therapeutics Treats First Patient with HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

8/6/18 – Pliant Therapeutics
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

8/3/18 – Pulse Biosciences
Pulse Biosciences Grants Equity Incentive Awards to New Employees

8/3/18 – San Francisco Business Times
Alexandria’s Joel Marcus on Medicare-for-all, innovation and his company’s Peninsula plans

8/3/18 – Wired
23andMe’s Pharma Deals Have Been the Plan All Along